ZULRESSO®

ApprovedCompleted

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Postpartum Depression

Conditions

Postpartum Depression

Trial Timeline

Oct 8, 2021 → Jul 14, 2022

NCT ID

NCT05059600

About ZULRESSO®

ZULRESSO® is a approved stage product being developed by Supernus Pharmaceuticals for Postpartum Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT05059600. Target conditions include Postpartum Depression.

What happened to similar drugs?

2 of 9 similar drugs in Postpartum Depression were approved

Approved (2) Terminated (0) Active (7)

✅Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved

✅Eptacog alfa (NovoSeven)Novo NordiskApproved

🔄Misoprostol + OxytocinCiplaPhase 3

🔄aripiprazoleBristol Myers SquibbPhase 3

🔄SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg CapsulesBiogenPhase 3

🔄SAGE-217 + PlaceboBiogenPhase 3

🔄LPCN 1154A + PlaceboLipocinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05059600	Approved	Completed	Oct 8, 2021	Jul 14, 2022	Postpartum Depression

Competing Products

20 competing products in Postpartum Depression

See all competitors

Product	Company	Stage	Hype Score
Misoprostol + Oxytocin	Cipla	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	27
Azithromycin + Azithromycin and amoxicillin + Placebo	Merck	Approved	43
Eptacog alfa (NovoSeven)	Novo Nordisk	Approved	50
Eptacog alfa (activated)	Novo Nordisk	Pre-clinical	26
aripiprazole	Bristol Myers Squibb	Phase 3	40
fibrinogen concentrate + Placebo	CSL	Phase 1/2	24
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules	Biogen	Phase 3	37
SAGE-217 + Placebo	Biogen	Phase 3	37
Zuranolone	Biogen	Pre-clinical	30
Zuranolone	Biogen	Pre-clinical	30
LPCN 1154A + Placebo	Lipocine	Phase 3	30
Goserelin 3.6 mg implant + Placebo	Brain Biotech	Pre-clinical	16
ZULRESSO (brexanolone) injection	Supernus Pharmaceuticals	Pre-clinical	20
Placebo + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
SAGE-547	Supernus Pharmaceuticals	Phase 2	29
Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
SAGE-547 + Placebo	Supernus Pharmaceuticals	Phase 2	29
GH001	GH Research	Phase 2	21
Brexanolone	Brain Biotech	Pre-clinical	16